Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Br J Haematol. 2020 Jul;190(1):40-44. doi: 10.1111/bjh.16514. Epub 2020 Feb 27.
Serum thymus and activation regulated chemokine (TARC) levels reflect classical Hodgkin lymphoma (cHL) disease activity and correspond with treatment response. We compared mid-treatment interim TARC (iTARC) with interim F-fluorodeoxyglucose positron-emission tomography (iPET) imaging to predict modified progression-free survival (mPFS) in a group of 95 patients with cHL. High iTARC levels were found in nine and positive iPET in 17 patients. The positive predictive value (PPV) of iTARC for a 5-year mPFS event was 88% compared to 47% for iPET. The negative predictive value was comparable at 86% for iTARC and 85% for iPET. Serum iTARC levels more accurately reflect treatment response with a higher PPV compared to iPET.
血清胸腺和激活调节趋化因子（TARC）水平反映经典霍奇金淋巴瘤（cHL）的疾病活动情况，并与治疗反应相对应。我们比较了 95 例 cHL 患者治疗中期的 TARC（iTARC）与中期 F-氟脱氧葡萄糖正电子发射断层扫描（iPET）成像，以预测改良无进展生存期（mPFS）。9 例患者 iTARC 水平较高，17 例患者 iPET 阳性。与 iPET 相比，iTARC 对 5 年 mPFS 事件的阳性预测值（PPV）为 88%，而 iPET 为 47%。阴性预测值方面，iTARC 和 iPET 分别为 86%和 85%，两者相当。与 iPET 相比，血清 iTARC 水平更能准确反映治疗反应，其阳性预测值更高。
